In vitro evaluation of positive expiratory pressure devices attached to nebulizers

Respiratory Care

Volumn 59, Issue 2, 2014, Pages 216-222

  Berlinski, Ariel ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ARKANSAS CHILDREN S HOSPITAL RESEARCH INSTITUTE   (United States)

Author keywords

Aerosol characteristics; Albuterol; Nebulizer; Particle size; PEP; Vibratory PEP

Indexed keywords

SALBUTAMOL;

AEROSOL; ARTICLE; BREATHING RATE; FLOW RATE; HUMAN; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; NEBULIZATION; NEBULIZER; PARTICLE SIZE; POSITIVE END EXPIRATORY PRESSURE VENTILATOR; SPECTROPHOTOMETRY;

AEROSOL CHARACTERISTICS; ALBUTEROL; NEBULIZER; PARTICLE SIZE; PEP; VIBRATORY PEP;

ADULT; ALBUTEROL; BRONCHODILATOR AGENTS; CHILD; CYSTIC FIBROSIS; EQUIPMENT DESIGN; HUMANS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POSITIVE-PRESSURE RESPIRATION;

EID: 84893276255     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.02698     Document Type: Article

References (15)

1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373(9678):1891-904.
2. Mogayzel PJ Jr., Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013 Apr 1;187(7):680-9.
3. Lester MK, Flume PA. Airway-clearance therapy guidelines and implementation. Respir Care 2009;54(6):733-50; discussion 751-3.
4. Smiths Medical. Respiratory care products brochure. http://www. smiths-medical.com/upload/products/pdf/Respiratory%20care%20 brochure.pdf. Accessed on May 5, 2013.
5. Darquenne C. Aerosol deposition in health and disease. J Aerosol Med Pulm Drug Deliv 2012;25(3):140-7.
6. Laube BL, Geller DE, Lin TC, Dalby RN, Diener-West M, Zeitlin PL. Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosis. Respir Care 2005;50(11):1438-44.
7. Dornelas de Andrade A, Mesquita F, Galindo Filho V, Menezes MJ, Ferreira Neto JL, Almeida Filho P, et al. Effects of the Acapella device in radioaerosol regional pulmonary deposition (abstract). Eur Respir J 2007;30:222.
8. Berlinski A, Hayden JB. Optimization of a procedure used to measure aerosol characteristics of nebulized solutions using a cooled next generation impactor. J Aerosol Med Pulm Drug Deliv 2010,23(6): 397-404.
9. 2.9.44 Preparations for nebulization: characterization. Pharmeuropa 2006;18(2):280-283.
10. Aerosols, nasal sprays, metered dose inhalers and dry powder inhalers. US Pharmacopeia 28;2359-2377.
11. Laube BL, Jashnani R, Dalby RN, Zeitlin PL. Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate. Chest 2000;118(4):1069-1076.
12. Barry PW, O'Callaghan C. An in vitro analysis of the output of salbutamol from different nebulizers. Eur Respir J 1999;13(5): 1164-1169.
13. Mitchell J, Avvakoumova V, Schneider H, Ali R, Nagel M. Combining inhalation by a breath-actuated nebulizer (BAN) with exhalation through an oscillating positive pressure device (OPEP) offers the potential for optimal combined therapy (abstract). Am J Respir Crit Care Med 2013;187:A4116.
14. Geller DE. The science of aerosol delivery in cystic fibrosis. Pediatr Pulmonol 2008;43:S5-S17.
15. Usmani OS, Biddiscombe MF, Nightingale JA, Underwood SR, Barnes PJ. Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J Appl Physiol 2003;95(5): 2106-2112.